Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 22

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 22
---
 debate and unrest. Actual
or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate
adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects.

Our failure to regain and maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of the Common Shares.

The Common Shares are currently
listed for trading on Nasdaq. We must satisfy Nasdaq’s continued listing requirements, including, among other things, a minimum
bid price requirement of $1.00 per Common Share and a minimum shareholders’ equity of $2.5 million, or risk delisting, which would
have a material adverse effect on our business.

On November 3, 2025, we received
the Notification Letter from the Listing Qualifications Department of Nasdaq, notifying us that we are no longer in compliance with Nasdaq
Listing Rule 5550(b)(1). The Minimum Stockholders’ Equity Rule requires companies listed on The Nasdaq Capital Market to maintain
a minimum of $2,500,000 in stockholders' equity for continued listing. However, based on our Form 6-K filed on September 11, 2025, where
the Company filed its unaudited condensed interim consolidated financial equity for the three and nine months ended July 31, 2025,
filed on September 11, 2025, we reported a stockholders’ deficit of $1,065,668 and do not meet the alternatives of market value
of listed securities or net income from continuing operations, and we are thus non-compliant with the Minimum Stockholders’ Equity
Rule. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days, or until December 18, 2025, to submit a plan to regain
compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from receipt of the Notification Letter
to evidence compliance. However, there can be no assurance that our plan will be accepted or that we will be able to regain compliance
with the Minimum Stockholders’ Equity Rule.

Our failure to meet these
requirements may result in our securities being delisted from Nasdaq. A delisting could substantially decrease trading in the Common Shares,
adversely affect the market liquidity of the Common Shares as a result of the loss of market efficiencies associated with Nasdaq and the
loss of federal preemption of state securities laws,